BioPharmSignal logoBioPharmSignal

Biotech News

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

GH Research (GHRS)GH ResearchFDA / regulatory

GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Company to seek FDA alignment on global Phase 3 program replicating Phase 2b design Phase 3 initiation targeted for 2026 DUBLIN, Jan. 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage

Related news

GHRSGH Research2026-08-06 11:00 EST

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

GANXGain Therapeutics2026-06-29 20:05 EST

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

CGTXCognition Therapeutics2026-05-21 11:30 EST

Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

AXSMAxsome2026-07-15 11:00 EST

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

GHRSGH Research2026-06-04 11:00 EST

GH Research Announces Publication of Phase 2a Postpartum Depression Results

VYGRVoyager Therapeutics2026-06-01 12:00 EST

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

TNXPTonix Pharmaceuticals2026-08-03 11:00 EST

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

PRAXPraxis Precision Medicines2026-06-29 20:30 EST

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

View all latest news

GH Research

Neuropsychiatric Therapeutics Company GH Research develops therapies intended to produce rapid and durable responses in psychiatric and neurological disorders. GH001 GH001 is an inhaled formulation of mebufotenin being advanced as a rapid-acting treatment for treatment-resistant depression. Phase 2b results demonstrated remission signals...

Recent company news

GHRSGH Research2026-08-06 11:00 EST

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

GHRSGH Research2026-06-04 11:00 EST

GH Research Announces Publication of Phase 2a Postpartum Depression Results

GHRSGH Research2026-05-14 11:00 EST

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

GHRSGH Research2026-04-29 12:00 EST

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GHRSGH Research2026-04-20 13:00 EST

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

Stock data

Close
28.33 USD
Market cap
1.71B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States